Table 4. Grade 3/4 adverse events per patient treated at the MTD (all cycles).
|
NCI-CTC grade, n (%) (N=29)
|
||
|---|---|---|
| Event | 3 | 4 |
| Haematological | ||
| Anaemia | 0 | 0 |
| Leucopaenia | 1 (3) | 0 |
| Neutropaenia | 1 (3) | 0 |
| Thrombocytopaenia | 0 | 0 |
| Non-haematological | ||
| Alopecia | NA | NA |
| Anorexia | 0 | 0 |
| Lethargy | 1 (3) | 0 |
| Nausea | 0 | 0 |
| Vomiting | 0 | 0 |
| Diarrhoea | 3 (10) | 0 |
| Constipation | 0 | 0 |
| AST elevation | 1 (3) | 0 |
| Neuropathy | 1 (3) | 0 |
| Hand–foot syndrome | 0 | 0 |
| Infection | 0 | 0 |
| Abdominal pain | 2 (7) | 0 |
| Cardiac | 0 | 1 (3) |
AST=aspartate aminotransferase; MTD=maximum tolerated dose; NA=not applicable; NCI-CTC=National Cancer Institute Common Toxicity Criteria.